Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
J Antimicrob Chemother. 2010 Feb;65(2):218-23. doi: 10.1093/jac/dkp447. Epub 2009 Dec 16.
Raltegravir (Isentress) is the first approved HIV integrase inhibitor. Agents in this class target a different viral enzyme compared with agents inhibiting reverse transcriptase and protease. A wide number of patients are currently susceptible to integrase inhibitors, including heavily antiretroviral-experienced patients harbouring drug-resistant viruses. The good tolerability and convenience of raltegravir have recently begun to be appreciated, leading to the consideration of other indications for the drug. Data recently released using the drug as first-line therapy or in switch strategies are very promising and the role of raltegravir in intensification therapy is currently under investigation. Altogether, the current information supports a broad use of raltegravir beyond its initial approval for antiretroviral-experienced HIV-infected patients.
拉替拉韦（Isentress）是首个获得批准的 HIV 整合酶抑制剂。与抑制逆转录酶和蛋白酶的药物相比，该类药物针对的是不同的病毒酶。目前，大量患者对整合酶抑制剂敏感，包括携带耐药病毒的大量抗逆转录病毒治疗经验丰富的患者。拉替拉韦良好的耐受性和便利性最近开始受到重视，导致人们考虑该药的其他适应症。最近发布的数据显示，该药作为一线治疗或转换策略非常有前途，拉替拉韦在强化治疗中的作用目前正在研究中。总的来说，目前的信息支持在最初批准用于有抗逆转录病毒治疗经验的 HIV 感染患者之外，更广泛地使用拉替拉韦。
